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Abstract  1 
Aims: Cardiac hypertrophy is elicited by endothelin (ET)-1 as well as other 2 
neurohumoral factors, hemodynamic overload, and oxidative stress; HMG-CoA 3 
reductase inhibitors (statins) were shown to inhibit cardiac hypertrophy partly via the 4 
anti-oxidative stress. One of the common intracellular pathways of them is the 5 
phosphorylation cascade of MEK signaling. Pin1 specifically isomerizes the 6 
phosphorylated protein with Ser/Thr-Pro bonds and regulates their activity through 7 
conformational changes. There is no report whether the Pin1 activation contributes to 8 
ET-1-induced cardiomyocyte hypertrophy and whether the Pin1 inactivation contributes 9 
to the inhibitory effect of statins. The aim of this study was to reveal these questions.   10 
Main methods: We assessed neonatal rat cardiomyocyte hypertrophy using ET-1 and 11 
fluvastatin by the cell surface area, ANP mRNA expression, JNK and c-Jun 12 
phosphorylation, and [3H]-leucine incorporation.   Key findings: Fluvastatin inhibited 13 
ET-1-induced increase in the cell surface area, ANP expression, and [3H]-leucine 14 
incorporation; and it suppressed the signaling cascade from JNK to c-Jun. The 15 
phosphorylated Pin1 level, an inactive form, was decreased by ET-1; however, it 16 
became basal level by fluvastatin. Furthermore, Pin1 overexpression clearly elicited 17 
cardiomyocyte hypertrophy, which was inhibited by fluvastatin.   Significance: This is 18 
the first report that ET-1-induced cardiomyocyte hypertrophy is mediated through the 19 
Pin1 activation and that the inhibitory effect of fluvastatin on cardiomyocyte hypertrophy 20 
would partly be attributed to the suppression of the Pin1 function. This study firstly 21 
suggests that Pin1 determines the size of hypertrophied cardiomyocyte by regulating 22 
the activity of phosphorylated molecules and that statins exert their pleiotropic effects 23 
partly via Pin1 inactivation.  24 
25 
 3 
Introduction 1 
   Cardiac hypertrophy is elicited by endothelin (ET)-1 (Suzuki et al., 1990; Yorikane et 2 
al., 1993; Ito et al., 1997; Koleitis et al., 2013; Miyauchi and Goto, 2013) as well as other 3 
neurohumoral factors, hemodynamic overload, and oxidative stress. One of the 4 
common intracellular pathways of them is the phosphorylation cascade of MEK 5 
signaling. Peptidyl-prolyl cis-trans isomerase 1 (Pin1) is a highly conserved enzyme that 6 
isomerizes specific phosphorylated Ser/Thr-Pro bonds in certain proteins, inducing 7 
conformational changes (Lu et al., 1996). It has been reported that Pin1 has the binding 8 
activity to the pSer/Thr-Pro pocket of target protein and that Pin1 catalyzes such portion. 9 
Both of these activities are exerted when the Ser-16 residue of Pin1 is 10 
dephosphorylated; on the other hand, these activities are inhibited when the residue is 11 
phosphorylated (Lu et al., 2007). The family of proline-directed protein kinases 12 
containing a major regulatory phosphorylation motif (pSer/Thr-Pro) includes c-Jun, Akt, 13 
cyclin dependent kinases, Raf-1, SMAD2/SMAD3, etc., which play an important role in 14 
the regulation of cell proliferation, tumorigenesis, neurological disorders, and 15 
autoimmune and inflammatory diseases (Lee et al., 2011). 16 
   The endothelin (ET) system consists of two G protein coupled-receptors, ET type A 17 
receptor and ET type B receptor, and three endogenous ligands, ET-1, ET-2, and ET-3 18 
(Davenport, 2002; Horinouchi et al., 2013; Koleitis et al., 2013; Miyauchi and Goto, 19 
2013). ET-1, a potent vasoconstrictive peptide produced by endothelial cells 20 
(Yanagisawa et al.,1988), is also produced by cardiomyocytes and contributes to the 21 
development of cardiac hypertrophy (Ito et al., 1991; Yorikane et al., 1993; Koleitis et al., 22 
2013; Miyauchi and Goto, 2013). We reported that the production of ET-1 is markedly 23 
increased in the failing hearts of rats with chronic heart failure (Sakai et al., 1996a; 24 
Sakai et al., 1996b) and that the enhancement of myocardial ET-1 contributes to the 25 
modulation of the cardiac function (Sakai et al., 1996a) and cardiac hypertrophy at the 26 
 4 
molecular level in the failing hearts (Sakai et al. 2000); moreover, chronic administration 1 
of the ETA receptor antagonist BQ-123 inhibits the cardiac remodeling and ameliorates 2 
the cardiac function (Sakai et al., 1996b). In addition, the signaling cascades of the 3 
mitogen activated protein kinase (MEK) family including extracellular signal-regulated 4 
kinase (ERK) and c-Jun N-terminal kinase (JNK) are augmented by ET-1 in 5 
cardiomyocyte hypertrophy (Yue et al., 2000; Irukayama-Tomobe et al., 2004; Shimojo 6 
et al., 2006). Therefore, in the present study, we hypothesized that Pin1 contributes to 7 
the development of cardiomyocyte hypertrophy through the activation of phosphorylated 8 
kinases of the MEK family by exerting its catalytic activity.  9 
   3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) 10 
are widely employed classes of cholesterol-lowering drugs that work through the 11 
inhibition of HMG-CoA reductase. Much evidence has demonstrated that statins reduce 12 
the cardiovascular risk to a greater extent than that expected based on the blood 13 
cholesterol-lowering effect alone; those additional activities of statins are known as 14 
pleiotropic effects including the suppression of inflammation and improvement of 15 
endothelial dysfunction (Wierzbicki et al., 2003). We have reported that pitavastatin 16 
ameliorates the severity of experimental autoimmune myocarditis through the inhibition 17 
of T-cell mediated autoimmunity (Tajiri et al., 2013). It was reported that statins interfere 18 
with the protein (iso)prenylation processes (Wierzbicki et al., 2003), which may be 19 
involved in the regulation of several cellular mechanisms such as signal transduction 20 
and cell proliferation and differentiation, etc. Previous studies have shown that statins 21 
inhibit cardiomyocyte hypertrophy provoked by angiotensin II by blocking the Rho 22 
kinase-mediated cyclin D1 activation (Morikawa-Futamatsu et al., 2006) and that an 23 
antioxidant mechanism involving Rac1 inhibition (Takemoto et al., 2001). Such reports 24 
suggest that another unresolved mechanism for the pleiotropic effects of statins 25 
remains.  26 
 5 
   However, there is no report whether the Pin1 activation is involved in cardiomyocyte 1 
hypertrophy provoked by ET-1; therefore, we hypothesized that the activation of Pin1 2 
activity would contribute to the ET-1-induced cardiomyocyte hypertrophy. In addition, 3 
there is no report whether the inhibitory effect of statins on the ET-1-induced 4 
cardiomyocyte hypertrophy is mediated through the modulation of the Pin1 activity. The 5 
aim of this study was to reveal these questions. 6 
 7 
Materials and Methods 8 
Adenovirus vectors    Human Pin1 cDNA cloned from 293A cells by PCR using the 9 
following primers, (Forward) 5’-CACCATGGCGGACGAGGAGAAGCT-3’ and (Reverse) 10 
5’-CTCAGTGCGGAGGATGATGTGGATG-3’, was ligated to the pENTR-TOPO plasmid 11 
as an entry clone; cDNA was transferred to the pAd/CMV/V5-DEST Gateway vector by 12 
an LR recombination (Life Technologies, Carlsbad, CA). The cDNA for human Pin1 was 13 
designed to add the V5 tag at C-termianl of the entire Pin1 fusion protein. The 14 
adenovirus vector plasmid was digested by Pac I, transfected to 293A cells and 15 
amplified, and finally purified by a Vivaspin column system (Sartorius Stadium 16 
Biotechnology, Goettingen, Germany). As a control, an adenovirus vector of LacZ was 17 
used. Adenovirus for an enhanced green fluorescent protein (EGFP) was used to 18 
visualize the morphology of the cardiomyocytes and to take photographs. 19 
Cardiomyocyte culture   Neonatal rat cardiomyocytes were isolated from 2- to 20 
3-day-old Sprague-Dawley rats, as described previously (Shimojo et al., 2007; Sakai et 21 
al., 2012), and were incubated on fibronectin-coated dishes in DMEM-Ham's F-12 22 
medium (Wako) supplemented with 0.1% fatty acid-free bovine serum albumin (BSA) 23 
(Sigma, St. Louis, MO) in 95% air-5% CO2. The cells were cultured for 2 days after the 24 
differential adhesion and then used for further experiments. The animal experiment for 25 
 6 
cardiomyocyte isolation was carried out in a humane manner after we received approval 1 
from the Institutional Animal Experiment Committee of University of Tsukuba and were 2 
in accordance with the Regulation for Animal Experiments in our university.   3 
Study Protocol   Cardiomyocytes were pretreated with a vehicle or fluvastatin (0.1-10 4 
M) (Wako Pure Chemical Industries, Osaka, Japan) and 12 hours later, human/rat 5 
ET-1 (10 nM) (Peptide Institute Inc., Osaka, Japan) was applied and incubated for 48 6 
hours; the cell surface area was evaluated as describing below; and the sampling for 7 
the [3H]-leucine uptake, real-time PCR, and Pin1 expression was done in an individual 8 
experiment. A Western blot was performed for ERK, JNK, and c-Jun, and the samples 9 
were collected 30 minutes after the ET-1 stimulation. In the transient transfection 10 
experiments, cardiomyocytes were transfected with an adenovirus for Pin1 or LacZ 11 
(control) at a titer with 20 multiplicity of an infection (MOI); in the experiment of taking 12 
photographs of cardiomyocytes, the adenovirus for EGFP (10 MOI) was transfected 13 
additionally; 12 hours later after adenoviral transfection, cardiomyocytes were treated 14 
with a vehicle or fluvastatin and harvested for 48 hours. There are some reasons why 15 
we selected fluvastatin in this experiments; (1) as fluvastatin is known as one of 16 
lipophilic statins contrasted to a hydrophilic statin, pravastatin, and is suspected to be 17 
easily incorporated into the muscle cells, it suggested us that using fluvastatin leads the 18 
easier evaluation for determining the inhibitory effect of statin on cardiomyocyte 19 
hypertrophy; (2) other researchers previously reported that fluvastatin has the inhibitory 20 
effect on cardimyocyte hypertrophy (Morikawa-Futamatsu et al., 2006); and (3) other 21 
lipophilic statins, simvastatin and atorvastatin were reported to prevent cardiac 22 
hypertrophy (Liu et al., 2008; Indolfi et al., 2002; Planavila et al., 2005).  23 
Cardiomyocyte size measurement   Cardiomyocytes were observed by microscope 24 
(DM1L, Leica Japan, Tokyo, Japan) and captured by a charge-coupled device camera 25 
(Olympus, Tokyo, Japan). The surface area of the attached cardiomyocytes on the dish 26 
 7 
(the area of cardiomyocytes in 2D image) for 10 cells/field with 5 fields in each group 1 
was evaluated by the software NIH ImageJ ver 1.47 (National Institute of Health, 2 
Bethesda, MD) and repeated by 3 times.   3 
Protein synthetic rate   The rates of protein synthesis in cultured neonatal rat 4 
cardiomyocytes were assessed by measuring the [3H]-leucine uptake into acid-insoluble 5 
cellular materials as described previously (Sano et al., 2002; Shimojo et al., 2007). The 6 
cells were plated on 24-well dishes at a density of 1x105 cells/well and pretreated with 7 
fluvastatin or vehicle 12 hours before the ET-1 stimulation. Twenty-four hours after the 8 
ET-1 treatment, 0.1 mCi/ml [3H]-leucine (GE Healthcare, Piscataway, NJ) was added 9 
and the cells were incubated for 24 hours. The cells were finally fixed by 5% 10 
trichloroacetic acid and detached by 0.25% trypsin, and the cell residues were 11 
solubilized in 0.5M NaOH. Aliquots were counted with a scintillation counter (LS-6500 12 
scintillation counter; Beckman Coulter, Fullerton, CA). In the transient transfection assay, 13 
cardiomyocytes were transfected with an adenovirus for Pin1 or LacZ; 12 hours later, 14 
fluvastatin or vehicle was added and cardiomyocytes were incubated for 48 hours; 15 
[3H]-leucine was added and incubated for last 24 hours.  16 
Gene expression analysis   The total RNA from 1x106 cardiomyocytes was isolated 17 
using RNeasy (Qiagen, Valencia, CA) and was reverse transcribed to cDNA by a 18 
synthesis kit (Qiagen). The mRNA expression levels of the target genes were analyzed 19 
by real-time quantitative PCR with a TaqMan probe using an ABI Prism 7700 sequence 20 
detector (Applied Biosystems, Foster, CA), as described previously (Shimojo et al., 21 
2007; Sakai et al., 2012).  The commercially available gene-specific primers and 22 
TaqMan probe sets were obtained from AppliedBiosystems. The PCR mixture (25 23 
microL total volume) consisted of forward and reverse primers for each gene at 450 nM 24 
each, FAM-labeled primer probes at 200 nM, and a TaqMan Universal PCR Master Mix 25 
(AppliedBiosystems). PCR amplification was performed in duplicate as follows: 1 cycle 26 
 8 
at 95oC for 10 min and 40 cycles at 94 oC for 15 s and 60 oC for 1 min. The quantitative 1 
values of target mRNA were normalized by glyceraldehyde-3-phosphate 2 
dehydrogenase (GAPDH) mRNA expression. The primers and probes sets were as 3 
follows: atrial natriuretic peptide (ANP), Rn00561661_m1; B-type natriuretic peptide 4 
(BNP), Rn00580641_m1; c-jun, Rn99999045_s1; and GAPDH, Rn01775763_g1.   5 
Western blot   Cardiomyocytes in a concentration of 2x106 from each group were 6 
lysed on ice with a buffer (10 mM Tris HCl, 150 mM NaCl, 1 mM ethylenediamine- N, N, 7 
N’, N’-tetraacetic acid [EDTA], 0.1% sodium dodecyl sulfate [SDS]), as described 8 
previously (Shimojo et al. 2007; Sakai et al. 2012). The protein concentration of the 9 
supernatant was determined with a bicinchoninic acid protein assay (Pierce, Rockford, 10 
IL). Samples were run on an SDS-polyacrylamide gel electrophoresis (PAGE), using 11 
10% or gradient 10-17.5% polyacrylamide gels, and electrotransferred to a PVDF 12 
membrane. To reduce any nonspecific binding, the membrane was blocked for 1 h at 13 
room temperature with 5% BSA or skim milk in tris-buffered saline (TBS) containing 14 
0.1% Tween 20 (TBST). Thereafter, the membrane was incubated overnight at 4oC with 15 
primary antibodies. We incubated the membrane with a horseradish 16 
peroxidase-conjugated goat anti-rabbit antibody or horse anti-mouse antibody (Cell 17 
Signaling Technology, Boston, MA) at 1:10000 in a TBST at room temperature for 60 18 
min. The blots were visualized with an enhanced chemiluminescence detection system 19 
(GE Healthcare), exposed to X-ray film or captured by CCD camera system (AE-6981, 20 
Atto Corporation, Tokyo, Japan), and analyzed by CS Analyzer (Atto Corporation). The 21 
following was used as the first antibodies: rabbit anti-Pin1, rabbit anti-phospho-Pin1, 22 
rabbit anti-p44/42 MAP Kinase, rabbit anti-phospho-p44/42 MAP Kinase, rabbit 23 
anti-SAPK/JNK, rabbit anti-phospho-SAPK/JNK, rabbit anti-c-Jun, rabbit 24 
anti-phospho-c-Jun (these antibodies were purchased from Cell Signaling Technology), 25 
mouse anti--actin (Sigma-Aldrich, St. Louis MO), and mouse anti-V5 (Life Technology).  26 
 9 
Statistical Analysis  The values are shown as means ± SE. Data were compared by a 1 
one-way ANOVA with a Turkey-Kramer’s HSD using the JMP ver 8.0 statistical software 2 
(SAS Institute, Cary, NC). Differences were considered significant at a P<0.05.  3 
 4 
Results 5 
Cardiomyocyte hypertrophy and fluvastatin:   The fluvastatin treatment markedly 6 
attenuated the increase in cell surface area stimulated by ET-1 in a dose-dependent 7 
manner (Figure 1A); the treatment with only fluvastatin alone slightly and significantly 8 
decreased the cardiomyocyte surface area more than the dosage of 1 M (Figure 1A). 9 
The fluvastatin treatment markedly inhibited the ET-1-induced increase of the protein 10 
synthesis evaluated by [3H]-leucine incorporation in a dose-dependent manner (Figure 11 
1B); the treatment with fluvastatin alone significantly suppressed the incorporation only 12 
at the dosage of 10 M (Actual values were followings: ET-1 [E] 0 [nM], Fluvastatin [F] 0 13 
[M], 5125 ± 294 [cpm, mean ± SE]; E0, F0.1, 4498 ± 405; E0, F1, 3791 ± 125; E0, F10, 14 
2415 ± 149; E10, F0, 7348 ± 406; E10, F0.1, 7144 ± 677; E10, F1, 5159 ± 29; E10, F10, 15 
3586 ± 89) (Figure 1B). These data indicated that fluvastatin has an inhibitory effect on 16 
cardiomyocyte hypertrophy provoked by ET-1. Moreover, there was a possibility that 17 
fluvastatin has a cytotoxic effect at a dosage of 10 M, because of the marked 18 
suppression in protein synthesis at this dosage and of the report that 3 M fluvastatin 19 
induced apoptosis in cardiomyocyte (Ogata et al., 2002); therefore, we used fluvastatin 20 
at a dosage of 1 M when we analyzed the effect of fluvastatin on cardiomyocyte. The 21 
mRNA expression of the cardiomyocyte hypertrophy markers ANP and BNP was 22 
significantly increased by ET-1, and fluvastatin significantly decreased both expressions 23 
 10 
(Figures 2A, 2B), suggesting that the inhibitory effect of fluvastatin on hypertrophy was 1 
also confirmed by the alteration of the hypertrophy markers.  2 
Intracellular signaling of cardiomyocyte hypertrophy and fluvastatin:  Fluvastatin 3 
markedly decreased both phospho-JNK and phospho-c-Jun level activated by ET-1 4 
(Figure 3B), suggesting the inhibition of the JNK pathway by fluvastatin; however, 5 
fluvastatin did not alter the phospho-ERK level augmented by ET-1 (Figure 3A). These 6 
data suggest that the inhibitory effect of fluvastatin on cardiomyocyte hypertrophy is 7 
mediated mainly via the JNK pathway rather than ERK. One of the downstream targets 8 
of JNK is c-Jun, which consists the transcription factor activator protein-1 (AP-1) as the 9 
homodimer by itself or heterodimer with c-Fos. The increased expression of c-jun 10 
mRNA induced by ET-1 was significantly suppressed by fluvastatin (Figure 4A); 11 
phospho-c-Jun was augmented by ET-1, and fluvastatin markedly attenuated the 12 
phosphorylation (Figure 4B). These data suggest that the inhibitory effect of fluvastatin 13 
on cardiomyocyte hypertrophy is predominantly associated with the JNK to c-Jun 14 
signaling, although ET-1 mobilizes both the ERK and JNK pathways.  15 
Involvement of Pin1 in cardiomyocyte hypertrophy.   The phospho-Pin1 level was 16 
significantly lower in the cardiomyocytes stimulated by ET-1 than the control (without 17 
ET-1); the reduced phospho-Pin1 level was reversed to the control level by fluvastatin 18 
treatment (Figure 5). The data suggest that a functional alteration of Pin1 occurred in 19 
the hypertrophied cardiomyocyte induced by ET-1, and that fluvastatin inhibited the 20 
ET-1-induced cardiomyocyte hypertrophy partly via the normalization of Pin1 21 
phosphorylation. To study the role of Pin1 in the cardiomyocyte hypertrophy and how 22 
fluvastatin is involved in the Pin1 regulation, transient transfection of Pin1 was done 23 
using an adenovirus vector (Figures 6A-6E). Morphologically, Pin1 overexpression 24 
induced cardiomyocyte hypertrophy (Figures 6A, 6B, 6D) and fluvastatin inhibited the 25 
Pin1-induced hypertrophy (Figures 6B, 6C, 6D). These data suggested that a gain of 26 
 11 
the Pin1 function induces cardiomyocyte hypertrophy and that Pin1-induced 1 
hypertrophy is suppressed by fluvastatin. In Western blot analysis, the V5-tagged Pin1 2 
(Pin1-V5) transgene product was verified by the anti-V5 antibody; the expression level 3 
of endogenous Pin1 did not differ among 3 groups (LacZ, Pin1 without fluvastatin, and 4 
Pin1 with fluvastatin); exogenously transfected Pin1-V5 was detected at the upper part 5 
compared to endogenous Pin1 because of the increase in molecular weight; 6 
phosphorylated Pin1 level was markedly increased in Pin1-V5 transfected groups 7 
compared to LacZ group in this experimental condition and phosphorylated Pin1 level 8 
was tended to be increased in fluvastatin-treated Pin1 group compared to 9 
vehicle-treated Pin1 group (Figure 6E).   10 
 11 
 12 
Discussion 13 
   This is the first report that ET-1-induced cardiomyocyte hypertrophy is mediated 14 
through the Pin1 activation and that the inhibitory effect of fluvastatin on cardiomyocyte 15 
hypertrophy would partly be attributed to the suppression of the Pin1 function. These 16 
findings suggest that the ET-1-induced cardiomyocyte hypertrophy is mediated through 17 
the activation of Pin1, which may be a key molecule determining the size of 18 
hypertrophied cardiomyocytes; furthermore, this is the first study to demonstrate that 19 
the inhibitory effect of fluvastatin on ET-1-induced hypertrophy would partly be attributed 20 
to the suppression of the Pin1 function by affecting the signaling from JNK to c-Jun.  21 
 22 
Pin1 involvement in the cardiomyocyte hypertrophy  23 
   Pin1 is a small protein with an N-terminal WW domain and a C-terminal PPIase 24 
domain (Lu et al., 2007). The WW domain binds phosphorylated Ser/Thr-Pro 25 
(pSer/Thr-Pro) motifs; the PPIase domain catalyzes cis/trans-isomerization of the 26 
 12 
proline-containing peptides; thus, Pin1 changes the activity of interacting proteins (Lu et 1 
al., 2007). It has been reported that Pin1 is overexpressed in breast cancer and 2 
promotes Ras signaling by increasing the transcriptional activity of c-Jun (Wulf et al., 3 
2001). In the present study, ET-1 activated the ERK, JNK, and c-Jun, a downstream 4 
target of JNK, simultaneously, and ET-1 attenuated the phosphorylated Pin1, an inactive 5 
form of Pin1, suggesting that ET-1 increases the catalytic activity of Pin1. Human c-Jun 6 
has a phosphorylated Ser63/Pro73 sequence and is known to be one of the Pin1 target 7 
proteins (Wulf et al., 2001). Therefore, Pin1 may participate in ET-1-induced 8 
cardiomyocyte hypertrophy partly via the activation of c-Jun, a component of the 9 
transcription factor activator protein (AP)-1.  10 
   Recently, it has been reported that human JNK1, an upstream precursor of c-Jun, 11 
also has four pSer/Thr-Pro motifs and Thr-183 on JNK1 is critical for JNK1 activation 12 
and Pin1 binding (Park et al., 2012); therefore, Pin1 might participate in ET-1-induced 13 
hypertrophy via the activation of JNK as well as c-Jun. Furthermore, it has also been 14 
reported that ERK and c-Fos, a downstream target of ERK, have pSer/Thr-Pro motifs 15 
and that Pin1 can bind to ERK and c-Fos (Monje et al., 2005; Toko et al., 2013); it 16 
suggests that Pin1 is involved in cardiomyocyte hypertrophy by cooperating with c-Jun 17 
and c-Fos to regulate the AP-1-dependent gene transcription upon activation of the 18 
MEK family members. In addition, the C-terminal domain of the largest subunit in RNA 19 
polymerase II, the global regulator machinery of transcription, is phosphorylated at 20 
Ser-2 and Ser-5 residues prior to the Pro at hypertrophy (Sano et al., 2004; Sakai et al., 21 
2012); Pin1 would contribute to the activation of RNA polymerase II and be involved in 22 
the hypertrophic responses. Therefore, Pin1 may play an important role in the 23 
development of cardiomyocyte hypertrophy not only via the activation of c-Jun but also 24 
via several kinds of functional molecules.  25 
 26 
 13 
Inhibitory effect of fluvastatin on ET-1-induced cardiomyocyte hypertrophy  1 
   Some researchers have reported the inhibitory effects of statins on cardiac 2 
hypertrophy both in vivo and in vitro; simvastatin prevented cardiac hypertrophy induced 3 
by a pressure overload through p21ras inactivation (Indolfi et al., 2002) and angiotensin 4 
II-induced hypertrophy through an antioxidant mechanism involving Rac1 inhibition 5 
(Takemoto et al., 2001); and fluvastatin inhibited cardiac hypertrophy via the 6 
suppression of cyclin D1 linked to Rho kinase (Morikawa-Futamatsu et al., 2006). The 7 
finding of the present study that fluvastatin inhibited the cardiomyocyte hypertrophy 8 
induced by ET-1 is also expected from the previous research mentioned above, and not 9 
a surprising idea because cardiomyocyte stimuli including angiotensin II, ET-1, and a 10 
pressure overload finally activate similar signaling pathways, i.e., the activation of the 11 
MEK family and transcription factor AP-1 (Heineke and Molkentine. 2006).  12 
   The new finding of the present study was that the inhibitory effect of fluvastatin on 13 
hypertrophy could partly be mediated via the suppression of the Pin1 function; one of 14 
the Pin1 targets inactivated by fluvastatin was suspected to be the JNK to c-Jun 15 
pathway rather than ERK, because fluvastatin predominantly decreased the expression 16 
of phospho-JNK and phospho-c-Jun, but not phospho-ERK, under ET-1 stimulation. 17 
Cyclin D1, whose function is suppressed by statins, is also known to be a target of Pin1 18 
(Liou et al., 2002); therefore, there is a possibility that the involvement of cyclin D1 19 
inhibition by fluvastatin on the anti-hypertrophy effect is partly mediated via the 20 
suppression of Pin1.  21 
   In the transient transfection assay using Pin1 adenovirus vector, the gain of the Pin1 22 
function by the Pin1 overexpression caused cardiomyocyte hypertrophy, whereas 23 
fluvastatin attenuated the Pin1-induced hypertrophy. The ET-1-induced reduction in 24 
phospho-Pin1 level was reversed by fluvastatin (Fig 5), whereas the expression level of 25 
phospho-Pin1 did not differ significantly between in fluvastatin treated Pin1 group and in 26 
 14 
vehicle-treated Pin1 group (Figure 6E). Therefore, we consider a mechanism for an 1 
inhibition of Pin1-induced cardiomyocyte hypertrophy by fluvastatin with no alteration of 2 
the phospho-Pin1 level as followings. Because it has been reported that 3 
death-associated protein kinase 1 (DAPK1) inhibits the catalytic activity of Pin1 (Lee et 4 
al., 2011), it would be suspected that the suppressive effect of statins on Pin1-mediated 5 
hypertrophic response is partly be attributed to the magnitude of DAPK1 activation. 6 
Alternatively, the following discussion may be also possible. The overexpression 7 
experiment of Pin1 transgene, which was forcedly expressed by CMV promoter and out 8 
of the transcriptional control by primarily or secondarily statin-regulated transcriptional 9 
factors, is an artificial condition. Thus, the transgene product may be a large amount 10 
compared with the endogenous Pin1 protein; therefore, we could not detect a significant 11 
difference of phospho-Pin1 expression level between in vehicle-treated Pin1 group and 12 
in fluvastatin-treated Pin1. In addition to above consideration, the precise mechanism 13 
for statins in the inactivation of Pin1 function still remains to be resolved. 14 
 15 
Conclusion  16 
   The present study revealed for the first time that (1) ET-1-induced cardiomyocyte 17 
hypertrophy is mediated through the activation of Pin1, which may be a key molecule 18 
determining the size of hypertrophied cardiomyocyte; (2) the inhibitory effect of 19 
fluvastatin on ET-1-induced hypertrophy would partly be attributed to the suppression of 20 
the Pin1 function; (3) the pathway from JNK to c-Jun would be a major target of Pin1. 21 
These findings firstly suggest that Pin1 is an important molecule for aggravating cardiac 22 
hypertrophy and that the inhibition of the Pin1 function by HMG-CoA reductase 23 
inhibitors is a novel mechanism for pleiotropic effects of them.  24 
 25 
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Figure Legends 1 
Figure 1.   Fluvastatin inhibited ET-1-induced cardiomyocyte hypertrophy. ET-1 (10 2 
nM)-induced cardiomyocyte hypertrophy was inhibited by fluvastatin in a dose 3 
dependent manner evaluated by the cell surface area  (10 cells/field with 5 fields 4 
[n=50] in each combination) (A) and by [3H]-leucine uptake (4 wells [n=4] in each 5 
combination) (B). Data were analyzed by a one-way ANOVA and expressed as the 6 
mean ± SE. *P<0.05, **P<0.01 compared with the control (treatments without ET-1 and 7 
fluvastatin). #P<0.05, ##P<0.01 compared with only ET-1 treatment.  8 
 9 
Figure 2.   Effects of fluvastatin (Flu, 1 M) and ET-1 (10 nM) treatments on the 10 
expression of the cardiomyocyte hypertrophy markers. ANP mRNA (n=6 for each group) 11 
(A) and BNP mRNA (n=6 for each group) (B) evaluated by RT-PCR. GAPDH mRNA 12 
was used as an internal control. Data were analyzed by a one-way ANOVA and 13 
expressed as the mean ± SE. *P<0.05 compared with the control (treatments without 14 
ET-1 and fluvastatin). #P<0.05 compared with only ET-1 treatment. 15 
 16 
Figure 3.   Effects of fluvastatin (Flu, 1 M) and ET-1 (10 nM) treatments on the 17 
expression of ERK and JNK evaluated by a Western blot.  A, Representative blots 18 
showed the phospho-ERK and total ERK levels, and the bar graph represented the ratio 19 
of the blot intensity of the phospho-ERK to the total ERK (n=4 for each group); B, blots 20 
showed the phosph-JNK and total JNK, and the bar graph represented that of the 21 
phospho-JNK to the total JNK (n=4 for each group). Data were expressed as the mean 22 
± SE. **P<0.01 compared with the control (treatments without ET-1 and fluvastatin). 23 
##P<0.01 compared with ET-1 treatment.  24 
 25 
 25 
Figure 4.   Effects of fluvastatin (Flu, 1 M) and ET-1 (10 nM) treatments on the 1 
expression of c-Jun. A, Expression of c-jun mRNA expression, and the bar graph 2 
represented the ratio of the c-jun expression to the GAPDH expression (n=6 for each 3 
group); B, representative Western blots showing the phospho-c-Jun and total c-Jun, 4 
and the bar graph represented the ratio of the blot intensity of the phospho-c-Jun to the 5 
total c-Jun (n=4 for each group). Data were expressed as the mean ± SE. **P<0.01 6 
compared with the control (treatments without ET-1 and fluvastatin). #P<0.05 compared 7 
with ET-1 treatment. 8 
 9 
Figure 5.   Effects of fluvastatin (Flu, 1 M) and ET-1 (10 nM) treatments on the 10 
expression of phospho-Pin1 evaluated by a Western blot. Representative blots showing 11 
the phospho-Pin1 and total Pin1 levels, and the bar graph represented the ratio in the 12 
blot intensity of the phospho-Pin1 to the total Pin1. Relative expression level of the 13 
phospho-Pin1 to the total Pin1 (n=4 for each group). Data were expressed as the mean 14 
± SE. **P<0.01 compared with the control (no treatments). ##P<0.01 compared with 15 
ET-1 treatment.  16 
 17 
Figure 6.   Cardiomyocyte hypertrophy induced by Pin1 overexpression was inhibited 18 
by fluvastatin (1 M). Representative photographs of cardiomyocytes transiently 19 
transfected by adenoviruses (20 MOI); (A) LacZ (control), (B) Pin1, (C) Pin1 treated 20 
with fluvastatin. Cardiomyocytes were labeled by adenovirus for EGFP (10 MOI), 21 
additionally. Bar represents 100 M. D, The bar graph represented the [3H]-leucine 22 
uptake (4 wells [n=4] in each combination). E, Representative Western blot showing the 23 
phospho-Pin1, total Pin1, and V5 protein level overexpressed by the V5-tagged Pin1 24 
adenovirus transfection. Data were expressed as the mean ± SE. *P<0.05, **P<0.01 25 
compared with LacZ transfection without fluvastatin treatment. #P<0.05 compared with 26 
 26 
Pin1 transfection without fluvastatin treatment.  1 
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